Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Alector, Inc.NASDAQ: ALEC

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$1.04M, compared with -$29.97M a year earlier. Trailing-twelve-month gross profit was -$11.28M. Over 3 fiscal years it compounded at -56.0% a year.

Context

  • Gross profit amounted to 54.1% of revenue in FY2025, down 30.8 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$1.04M or moves back toward the trailing-twelve-month quarterly average of -$2.82M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.04M-116.6% QoQ
Last fiscal yearDec 2025
$11.38M+113.3% YoY
LTMMar 2026
-$11.28M-289.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.5%——
1 year+113.3%——
3-year CAGR-56.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
11.38M USD
Year-over-year change
+113.3%
4-year CAGR
-10.4%

Gross Profit vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -289.4% is the 7th highest of 8, against a peer median of +63.7%.
  • Gross profit amounts to 61.2% of revenue for ALEC, versus a peer median of 232.7%.
ALEC Competitors
Gross Profit for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRDOpus Genetics, Inc.LTM Mar 2026$5.95M USD+1.3%-29.1%49.6%
VORVor Biopharma Inc.LTM Mar 2026-$28K USD+98.4%——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$46K USD-4.5%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$149K USD+99.1%——
PEPGPepGen Inc.LTM Mar 2026-$1.72M USD-351.6%——
NKTXNkarta, Inc.LTM Mar 2026-$2.34M USD———
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
ALECAlector, Inc.LTM Mar 2026-$11.28M USD-289.4%-56.0%61.2%
FATEFate Therapeutics, Inc.LTM Mar 2026-$26.26M USD+63.7%—415.8%
Peer median (excluding ALEC) —+63.7%-29.1%232.7%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.